A new user was defined as having had a 6-month baseline period in THIN without previous prescriptions for either drug. Those initiating therapy with a combination of metformin and an SU were excluded from the study. Subjects who had received a diagnosis of bladder cancer before cohort entry were excluded to avoid misclassification of prevalent cancers as incident cancers. Subjects